Dichloroacetate attenuates hypoxia-induced resistance to 5-fluorouracil in gastric cancer through the regulation of glucose metabolism

Experimental Cell Research
Yi XuanYong Kwan Cho

Abstract

In this study, we investigated whether gastric cancer with hypoxia-induced resistance to 5-fluorouracil (5-FU) could be re-sensitized following treatment with low-dose dichloroacetate (DCA), an inhibitor of the glycolytic pathway. The expression profiles of hypoxia-inducible factor-1α (HIF-1α) and pyruvate dehydrogenase kinase-1 (PDK-1) were analyzed in tissues from 10 patients with gastric cancer who had different responses to adjuvant 5-FU treatment. For the in vitro assays, cell viability and apoptosis were evaluated with and without treatment with 20mM DCA in the AGS and MKN45 cell lines, as well as in PDK1 knockdown cell lines. The expression levels of HIF-1α and PDK-1 were both elevated in the tumor tissues relative to the normal gastric tissues of most patients who showed recurrence after adjuvant 5-FU treatment. Cellular viability tests showed that these cell lines had a lower sensitivity to 5-FU under hypoxic conditions compared to normoxic conditions. Moreover, the addition of 20mM DCA only increased the sensitivity of these cells to 5-FU under hypoxic conditions, and the resistance to 5-FU under hypoxia was also attenuated in PDK1 knockdown cell lines. In conclusion, DCA treatment was able to re-sensitize gastric can...Continue Reading

References

Aug 18, 1983·The New England Journal of Medicine·P W StacpooleR I Misbin
Jun 1, 1994·Cancer Metastasis Reviews·B A Teicher
Feb 22, 2001·Journal of the National Cancer Institute·M Höckel, P Vaupel
Mar 21, 2002·Nature Reviews. Cancer·Adrian L Harris
Apr 3, 2002·Trends in Molecular Medicine·Gregg L Semenza
May 2, 2003·Nature Reviews. Cancer·Daniel B LongleyPatrick G Johnston
Sep 18, 2003·Nature Reviews. Cancer·Gregg L Semenza
Apr 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H H HartgrinkM Sasako
May 8, 2004·Biochemical Pharmacology·Charlotte GruberVerena Jendrossek
Nov 22, 2005·Lancet·Goodarz DanaeiUNKNOWN Comparative Risk Assessment collaborating group (Cancers)
Nov 6, 2007·The New England Journal of Medicine·Shinichi SakuramotoUNKNOWN ACTS-GC Group
Apr 22, 2008·Gynecologic Oncology·Jason Y Y WongImmaculata De Vivo
Jun 11, 2008·Abdominal Imaging·Min Jung ParkByung-Tae Kim
Dec 19, 2008·International Journal of Clinical Oncology·Narikazu Boku
Dec 19, 2009·International Journal of Cancer. Journal International Du Cancer·Jun NakamuraKohji Miyazaki
May 14, 2010·Science Translational Medicine·E D MichelakisK C Petruk
Sep 11, 2012·Journal of Cellular Biochemistry·Yaozhong HuHe Huang
Nov 9, 2012·International Journal of Oncology·Hoon HurSang-Uk Han
Jan 31, 2013·European Journal of Nuclear Medicine and Molecular Imaging·Chang-Bae KongSoo-Yong Lee

❮ Previous
Next ❯

Citations

May 16, 2015·Expert Opinion on Therapeutic Targets·Helena PópuloPaula Soares
Sep 17, 2014·Expert Opinion on Investigational Drugs·Douglas W SborovPamela J Harris
May 23, 2015·Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia·Helena DoktorovaTomas Eckschlager
Mar 13, 2015·Investigational New Drugs·Quincy Siu-Chung ChuEvangelos D Michelakis
Aug 27, 2014·Biochimica Et Biophysica Acta·Shyam Kankotia, Peter W Stacpoole
Jan 15, 2015·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Adam Kinnaird, Evangelos D Michelakis
Feb 28, 2018·Chemical Communications : Chem Comm·Isabel Abánades LázaroRoss S Forgan
Nov 12, 2015·World Journal of Gastroenterology : WJG·Ching-Ying Huang, Linda Chia-Hui Yu
Dec 12, 2019·Frontiers in Oncology·Chung-Yen HuangLinda Chia-Hui Yu
Jan 18, 2020·Angewandte Chemie·Isabel Abánades LázaroRoss S Forgan
Jul 1, 2020·Experimental Biology and Medicine·Sukanya RoySanjukta Chakraborty
Jan 9, 2021·Neoplasia : an International Journal for Oncology Research·Fabrizio Marcucci, Cristiano Rumio
Dec 16, 2020·International Journal of Molecular Sciences·Sven de MeyMark De Ridder
Aug 24, 2018·ACS Applied Materials & Interfaces·Isabel Abánades LázaroRoss S Forgan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bioinformatics in Biomedicine

Bioinformatics in biomedicine incorporates computer science, biology, chemistry, medicine, mathematics and statistics. Discover the latest research on bioinformatics in biomedicine here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Cancer Metabolic Reprogramming (Keystone)

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Cancer Metabolism: Therapeutic Targets

Targeting the mechanisms by which cancer cells acquire energy for metabolic needs is a therapeutic target. Discover the latest research on cancer metabolism and therapeutic targets.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.